Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Other Non-Current Assets (2016 - 2025)

Sonoma Pharmaceuticals has reported Other Non-Current Assets over the past 15 years, most recently at $64000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 12.33% year-over-year to $64000.0; the TTM value through Dec 2025 reached $64000.0, down 12.33%, while the annual FY2025 figure was $74000.0, 12.12% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $64000.0 at Sonoma Pharmaceuticals, down from $84000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $308000.0 in Q4 2022 and troughed at $61000.0 in Q2 2024.
  • A 5-year average of $99650.0 and a median of $76500.0 in 2021 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 84.09% in 2021 and later skyrocketed 310.67% in 2022.
  • Year by year, Other Non-Current Assets stood at $75000.0 in 2021, then skyrocketed by 310.67% to $308000.0 in 2022, then tumbled by 74.68% to $78000.0 in 2023, then decreased by 6.41% to $73000.0 in 2024, then fell by 12.33% to $64000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for SNOA at $64000.0 in Q4 2025, $84000.0 in Q3 2025, and $80000.0 in Q2 2025.